CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,044 enrolled
Drug / intervention
Huaier Granuledrug
Likely dose
Huaier Granule 20gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01770431
NCT01770431Phase 4Completed
CompareCT.gov

A Multicenter, Randomized, Paralleled Control Clinical Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy

Qidong Gaitianli Medicines Co., Ltd·interventional·Posted Jan 17, 2013·Updated Oct 2, 2017

In Brief

A Phase 4 clinical trial evaluating Huaier Granule for Hepatic Carcinoma. Completed, enrolled 1,044 participants across 1 site.

Detailed Summary

To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and metastasis of hepatocarcinoma after radical hepatectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Carcinoma
CountriesChina
CollaboratorsHuazhong University of Science and Technology

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 17, 2013
Enrollment StartAug 1, 2011
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 13.5 years ago

Interventions

Huaier Granuledrug

Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.